Wyeth

Other

Exxonmobil Research and Engineering Company

American Home Products Corporation

Ligand Pharmaceuticals, Inc.

Eugene Anthony Terefenko

Puwen Zhang

Andrew Fensome

Jay Edward Wrobel

James Patrick Edwards

Lin Zhi

Todd Kevin Jones

Christopher Michael Tegley

Eugene John Trybulski

Jeffrey Curtis Kern

Horace Fletcher, Iii

Mark A Collins

Allen Wayne Burton

Russell Dushin

Thomas Richard Jones

Kevin Joseph Curran

Jonathan David Bloom

Gary Sondermann Grubb

Stanley Lang

Martin DiGrandi

Bryan O'Hara

An Thien Vu

Adma Ross

Casey Cameron McComas

Stephen Todd Cohn

Hilda B Vroman

Arthur Attilio Santilli

Paige Erin Mahaney

Diane Deborah Harrison

Joseph Peter Sabatucci

Andrew Q Viet

Michael Anthony Marella

Richard Winneker

Mobae Afeworki

Joseph M Falkowski

Gavin David Heffernan

William Jay Moore

Kanmi Mao

Richard Dale Coghlan

Fei Ye

Charles William Mann

Richard Page Woodworth, Jr

Randall J Meyer

Joel Adam Goldberg

Callain Younghee Kim

David John O'Neill

The zeolite UTD-1 may be formed under hydrothermal synthesis conditions using a directing agent that does not include a metal atom therein. Methods for synthesizing the zeolite UTD-1 may comprise: combining at least a silicon atom source and a directing agent having a structure of in an aqueous medium; forming the zeolite in the aqueous medium under hydrothermal synthesis conditions, such that the zeolite has a framework silicate with a cationic portion of the directing agent occluded within pores or channels of the framework silicate; and isolating the zeolite from the aqueous medium. The zeolite has a powder x-ray diffraction pattern with at least the following 2&#x3b8;scattering angles: 6.0&#xb1;0.12, 7.6&#xb1;0.1, 14.66&#xb1;0.15, 19.7&#xb1;0.15, 21.27&#xb1;0.15, 22.13&#xb1;0.15, 22.61&#xb1;0.15, and 24.42&#xb1;0.10 for a borosilicate form zeolite, or 6.0&#xb1;0.12, 7.6&#xb1;0.15, 14.55&#xb1;0.15, 19.64&#xb1;0.15, 21.01&#xb1;0.20, 21.90&#xb1;0.20, 22.34&#xb1;0.20, and 24.38&#xb1;0.20 for an aluminosilicate form zeolite.

Zeolite syntheses and directing agents

The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure directing agents.

EMM-37 materials and processes and uses thereof

The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

EMM-23 materials and processes and uses thereof

A process for synthesizing a DDR framework-type molecular sieve comprises crystallizing a reaction mixture comprising water, a source of silicon, and a structure directing agent, Q, selected from the group consisting of a methyltropinium salt, a 2,6,N,N-tetramethylpiperidinium salt, a 2,N,N-trimethylpiperidinium salt and mixtures thereof, wherein the reaction mixture has a molar ratio of water to silicon from 5 to 80 and a molar ratio of alkali or alkaline earth metal, M, to silicon less than 0.01.

Synthesis of DDR framework-type molecular sieves

Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R, R, R, R, R, and Qare defined herein.

Cyclothiocarbamate derivatives as progesterone receptor modulators

The present invention is directed to substituted propylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Substituted propylamine derivatives and methods of their use

The present invention is directed to arylamino-arylpropanolamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Arylamino-arylpropanolamine derivatives and methods of their use

The present invention is directed to aryl sulfamide derivatives of formula I: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

Aryl sulfamide derivatives and methods of their use

The present invention is directed to benzothiadiazolylphenylalkylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Benzothiadiazolylphenylalkylamine derivatives and methods of their use

This invention provides progesterone receptor modulators having the structure: wherein Rto R, X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.

7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Phenylaminopropanol derivatives and methods of their use

Growing community of inventors

Quakertown, PA, United States of America

Eugene Anthony Terefenko